Publication Name	World Journal of Clinical Cases
Manuscript ID	62617
Country	China

Received	2021-01-14 14:11
Peer-Review Started	2021-01-14 14:14
To Make the First Decision
Return for Revision	2021-02-11 01:49
Revised	2021-02-15 03:02
Second Decision	2021-05-19 13:00
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-05-20 01:20
Articles in Press	2021-05-20 01:20
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-05-24 19:41
Typeset the Manuscript	2021-07-02 09:17
Publish the Manuscript Online	2021-07-21 08:24

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Case Report
Article Title	Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports
Manuscript Source	Unsolicited Manuscript
All Author List	Shao-Ru Liu, Qing Yan, Hao-Ming Lin, Guang-Zi Shi, Yi Cao, Hong Zeng, Chao Liu and Rui Zhang
ORCID	Author(s) ORCID Number Shao-Ru Liu http://orcid.org/0000-0002-7353-6143 Qing Yan http://orcid.org/0000-0002-5934-6941 Hao-Ming Lin http://orcid.org/0000-0003-3373-7204 Guang-Zi Shi http://orcid.org/0000-0003-0170-7895 Yi Cao http://orcid.org/0000-0002-3722-357X Hong Zeng http://orcid.org/0000-0002-9811-0421 Chao Liu http://orcid.org/0000-0001-6659-4372 Rui Zhang http://orcid.org/0000-0003-3335-0931
Funding Agency and Grant Number	Funding Agency Grant Number The Special Research Foundation of the National Nature Science Foundation of China 81972262 The Special Research Foundation of the National Nature Science Foundation of China 81972255 The Guangdong Basic and Applied Basic Research Foundation 2018A030313645 The Guangdong Basic and Applied Basic Research Foundation 2020A1515010117 The Guangdong Basic and Applied Basic Research Foundation 2016A030313840 Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [2013]163 the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes KLB09001 Guangdong Science and Technology Department 2015B050501004 Guangdong Science and Technology Department 2017B030314026 Sun Yat-sen University Clinical Research 5010 Program 2018008
Corresponding Author	Rui Zhang, PhD, Doctor, Professor, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 33 YingFeng Road, Haizhu District, Guangzhou 510288, Guangdong Province, China. zhangr95@mail.sysu.edu.cn
Key Words	Case report; Recurrent hepatocellular carcinoma; Inferior vena cava tumor thrombus; Metastasis; Programmed cell death ligand 1; Immunotherapy
Core Tip	Recurrent hepatocellular carcinoma (HCC) with inferior vena cava tumor thrombus (IVCTT) is a great challenge for oncologists and has a poor prognosis. The safety and efficacy of programmed cell death ligand 1 inhibitors are still unknown. To the best of our knowledge, the first case is the first report of successful treatment of recurrent and metastatic HCC with inferior vena cava tumor thrombus with atezolizumab. We reported two other cases of HCC with IVCTT at the first diagnosis, for which patients were treated with a programmed cell death protein 1 inhibitor after surgery or recurrence, and both patients achieved a good outcome. Anti-programmed cell death ligand 1 therapy in HCC patients with IVCTT and metastasis is associated with relatively good patient outcomes.
Publish Date	2021-07-21 08:24
Citation	Liu SR, Yan Q, Lin HM, Shi GZ, Cao Y, Zeng H, Liu C, Zhang R. Anti-PD-L1 based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case report. World J Clin Cases 2021; 9(21): 5988-5998
URL	https://www.wjgnet.com/2307-8960/full/v9/i21/5988.htm
DOI	https://dx.doi.org/10.12998/wjcc.v9.i21.5988

Full Article (PDF)	WJCC-9-5988.pdf
Full Article (Word)	WJCC-9-5988.docx
CARE Checklist–2016	62617-CARE-Checklist–2016-revision.pdf
Manuscript File	62617-Review-Filipodia Not CL.docx
Answering Reviewers	62617-Answering reviewers.pdf
Audio Core Tip	62617-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	62617-Conflict-of-interest statement.pdf
Copyright License Agreement	62617-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	62617-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s)	62617-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	62617-Language certificate.pdf
Peer-review Report	62617-Peer-review(s).pdf
Scientific Misconduct Check	62617-Scientific misconduct check.pdf
Scientific Editor Work List	62617-Scientific editor work list.pdf